Ibrutinib (Imbruvica) has been listed on the PBS from August 1 for relapsed or refractory mantle cell lymphoma (MCL). The listing expands reimbursed access to the Bruton’s tyrosine kinase inhibitor beyond refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). It will also spare patients the high cost of $134,000 per year for a ...
PBS access to ibrutinib expanded to Mantle Cell Lymphoma
By Mardi Chapman
18 Jul 2018